AFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)

Novello, SilviaRamlau, RodrygGorbunova, Vera A.Ciuleanu, Tudor E.Ozguroglu, MustafaGoksel, TuncayBaldotto, ClarissaBennouna, JaafarShepherd, Frances A.Scagliotti, Giorgio2019-10-272019-10-2720111556-08641556-1380https://hdl.handle.net/11454/44420eninfo:eu-repo/semantics/closedAccessAngiogenesis inhibitorsVascular endothelial growth factor (VEGF)Phase III clinical trialsAFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)Conference Object66S470S470WOS:000208855802199Q1